nhl indolent & aggressive post ash 2024
Published 7 months ago • 18 plays • Length 1:04:53Download video MP4
Download video MP3
Similar videos
-
0:43
exciting advancements in nhl from eha 2024
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
2:13
ash news tv 2023: ash guideline implementation champions
-
1:37
eo2463: a vaccine as a monotherapy or in combination with standard chemotherapy in nhl
-
5:19
ash 2020: overview of the current advances in treating aggressive nhl
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
2:14:08
2024 annual immunisation update
-
34:40
updates in lymphoma - 2023 best of hematology conference
-
1:00:50
investigator perspectives on the role of bispecific antibodies in the management of lymphoma
-
1:35
update on phase i study of plamotamab in r/r nhl
-
1:13
ash news tv 2023: press briefings
-
8:06
findings from arms 6 and 7 of the epcore nhl-2 trial: epcoritamab in newly diagnosed fl
-
23:10
what’s new in follicular lymphoma: updates from asco 2024 & the eha hybrid congress
-
1:27
the next steps in the treatment of nhl
-
2:01
cll and lymphoma updates from ash: 2023 best of hematology
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
2:00
ash clinical news: june 2024 from the desk of...
-
1:17
the promise of bispecific antibodies in the treatment of nhl
-
6:37
brecadd regimen is superior in treating advanced hl: results from the hd21 trial
-
1:31
frontline treatment for cll: the changing paradigm